Navigation Links
Micromet Reports Fourth Quarter and Full Year 2009 Financial Results
Date:3/4/2010

aterially from any future results expressed or implied by any forward-looking statements include the risk that blinatumomab or our other product candidates do not demonstrate safety and/or efficacy in future clinical trials, delays in development and testing,  including the risk that we will not obtain approval to market blinatumomab, and the risks associated with reliance on outside financing to meet capital requirements. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2009, filed with the SEC on November 6, 2009, as well as other filings by the company with the SEC.

    
    
                                Micromet, Inc.
                    Condensed Consolidated Balance Sheets
                       (In thousands, except par value)
    
                                             December 31,   December 31,
                                                 2009           2008
                                             ------------   ------------
    Assets
    Current assets:
        Cash and cash equivalents                $113,434        $46,168
        Short-term investments                      4,169              -
        Accounts receivable                           464          3,424
        Prepaid expenses and other current
         assets                                     2,156          1,950
                                                    -----          -----
    Total current assets                          120,223         51,542
    Property and equipment, net                     3,959          3,322
    Goodwill                                        6,462          6,462
    Patents, net                                    1,016          5,250
    Deposits and other assets                           -            959
    Restricted cash                                 3,153         
'/>"/>
SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. Data from Phase 1 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Non-Hodgkins Lymphoma
2. Micromet, Inc. Reports Second Quarter 2009 Financial Results
3. Phase 1 Study Initiated with Micromet Anti-GM-CS Human Antibody MT203
4. Micromet, Inc. Reports First Quarter 2009 Financial Results
5. Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference
6. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society of Hematology Annual Meeting
7. Micromet to Present at the Piper Jaffray 20th Annual Health Care Conference
8. Micromet, Inc. Reports Second Quarter 2008 Financial Results
9. Micromet, Inc. Reports First Quarter 2008 Financial Results
10. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
11. Micromets BiTE(R) Antibodies Reveal Unique Mode of Action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Volunteers from the Church of Scientology of Denmark ... with massive distribution of Truth About Drugs ... on Strøget, the famous Copenhagen walking street. Popular ... its ambiance, some quarter of a million people stroll ... , These activities are part of a coordinating effort ...
(Date:7/30/2014)... SF Cable, distributor of the highest quality cables, ... internet with guaranteed customer satisfaction announces the availability of ... These lightning cords are MFI certified to meet Apple ... Cable Lightning to USB Cables feature the ... and syncing. Compatible with the iPhone 5S/5C/5 plus iPad ...
(Date:7/30/2014)... well as evolutionary changes in a living organismhad been ... the genome. , However, recent studies have shown that ... that arise simultaneously and in close proximity to each ... in regions where chromosomal rearrangements take place. , The ... may one day lead to new cancer therapies, according ...
(Date:7/30/2014)... New York (PRWEB) July 30, 2014 ... uncontrollable brain bleeding has filed a Xarelto lawsuit ( ... the blood thinner, Bernstein Liebhard LLP reports. According to ... for the District of Vermont on July 25th, the ... when he suffered an irreversible brain bleed that ultimately ...
(Date:7/30/2014)... MA (PRWEB) July 30, 2014 ... of authentication, access management and secure communications solutions ... Imprivata OneSign ® is the most widely selected ... McKesson Paragon or Horizon electronic medical records (EMR) ... increase of about 11 percent in the last ...
Breaking Medicine News(10 mins):Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2
... just received a major grant from the National Center ... the National Institutes of Health (NIH) and lead Federal ... new grant creates a Center of Excellence for Research ... will focus on Alzheimers disease. The new Center has ...
... 2007. A report to be published in an upcoming ... for urgent attention to the politically sensitive issue of border ... in the face of a catastrophic flu pandemic . ... of a strain of avian influenza A (HN51) in Northern ...
... today,announced it received a $250,000 grant from the ... support services. The university will use the ... professions. The newly created program, named the ... help the university recruit and support,Hispanic women in ...
... for Eating Disorders Reports Eating Disorders Develop or ... Worsen Upon Returning ... Eating Disorders, http://www.remudaranch.com, the nation,s leading eating disorder treatment,center, ... A majority of eating disorders begin at ages 14 and ...
... Governor,Arnold Schwarzenegger held a press conference announcing ... state legislature aimed at producing,reforms to California,s ... Policies Institute issued the following statement:, ... solve California,s,health care crisis," said Jill Jenkins, ...
... YORK, Oct. 10 Philip K. Howard, Chair of Common,Good, ... in response to a recent study on health courts that ... "The American Association of Justice (formerly known as the Association ... a study that it commissioned on the ...
Cached Medicine News:Health News:Mount Sinai recognized as Center of Excellence for Research in Alzheimer's disease 2Health News:Report highlights inadequate pandemic planning as a threat to EU security 2Health News:Wal-Mart Foundation Provides Brenau University $250,000 Health Care scholarships Grant for Hispanic Women 2Health News:Wal-Mart Foundation Provides Brenau University $250,000 Health Care scholarships Grant for Hispanic Women 3Health News:Going Back to School Can Trigger Eating Disorders 2Health News:Going Back to School Can Trigger Eating Disorders 3Health News:Common Good Responds to a Trial Bar Study Opposing Health Courts 2
(Date:7/30/2014)... 2014  Hologic, Inc. (NASDAQ: HOLX ) ... ended June 28, 2014. Third Quarter Financial ... to $632.6 million, reflecting operational growth of 0.5% and ... same period in the prior year. , Revenues ... Breast Health revenues grew 3.5%. , GYN Surgical ...
(Date:7/30/2014)... 2014  Cepheid (Nasdaq: CPHD ) ... Premier will end on September 30, 2014.  Customers ... able to continue their relationship with Cepheid through ... and ROi, in addition to the recently announced ... "Cepheid has always recognized and supported the ...
(Date:7/30/2014)... CryoLife, Inc. (NYSE: CRY), a leading medical device and ... announced today that its Board of Directors has approved ... of $0.03 per share of common stock outstanding.  The ... paid on September 19, 2014 to all common stockholders ... date for the quarterly dividend is September 10, 2014.  ...
Breaking Medicine Technology:Hologic Announces Third Quarter Fiscal 2014 Operating Results 2Hologic Announces Third Quarter Fiscal 2014 Operating Results 3Hologic Announces Third Quarter Fiscal 2014 Operating Results 4Hologic Announces Third Quarter Fiscal 2014 Operating Results 5Hologic Announces Third Quarter Fiscal 2014 Operating Results 6Hologic Announces Third Quarter Fiscal 2014 Operating Results 7Hologic Announces Third Quarter Fiscal 2014 Operating Results 8Hologic Announces Third Quarter Fiscal 2014 Operating Results 9Hologic Announces Third Quarter Fiscal 2014 Operating Results 10Hologic Announces Third Quarter Fiscal 2014 Operating Results 11Hologic Announces Third Quarter Fiscal 2014 Operating Results 12Hologic Announces Third Quarter Fiscal 2014 Operating Results 13Hologic Announces Third Quarter Fiscal 2014 Operating Results 14Hologic Announces Third Quarter Fiscal 2014 Operating Results 15Hologic Announces Third Quarter Fiscal 2014 Operating Results 16Hologic Announces Third Quarter Fiscal 2014 Operating Results 17Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 3CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2014 2CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2014 3
... AuraSense Therapeutics, a biopharmaceutical company commercializing spherical ... and chemo-therapeutics for a variety of diseases, ... for cardiovascular disorders, has closed its Series ... a subsidiary of Abbott.  Other key individual ...
... 2011 /PRNewswire-Asia/ -- The Ministry of Health and ... Industry Development Institute (President Ko Kyung-hwa) launched a ... foreign patients by designating 38 tasks, including seven ... for medical injuries and granting permission for drug ...
Cached Medicine Technology:AuraSense Therapeutics Secures Series B Equity Investment 2Medical Korea's Medical Policy Improvement Project for Foreign Patients 2
Kinetic and endpoint methods for the quantitative determination of creatinine in serum....
Intended for the quantitative determination of creatinine in serum, plasma, or urine. Reaction: Endpoint. Wavelength: 340 nm. Linearity: 10 mg/dL (880 mol/L). Two vials, dry powder reagents....
For the quantitative determination of creatine kinase-MB in serum. Kinetic Reaction measured at 340 nm. Linearity: 700 IU/L at 37C....
For the quantitative determination of creatine kinase in serum. Kinetic Reaction measured at 340 nm. Linearity: 1500 IU/L at 37C....
Medicine Products: